Antibodies are an essential tool for many applications including flow cytometric analysis, immunoprecipitation, enzyme-linked immunosorbent assay (ELISA), immunocytochemistry, western blotting, and immunohistochemistry which drives the monoclonal antibodies diagnostics reagent market. Moreover, monoclonal antibodies (MAbs) are significant diagnostic reagent used in microbiological research, biomedical research, and also in diagnosis of various diseases such as HIV, hepatitis, herpes simplex, influenza infections, chlamydia, as well as for the treatment of cancer. Presently, the rising prevalence of diseases and infections is a major driving factor driving the global market. Additionally, increasing research & developmental activity in the diagnostic field is likely to act as a growth engine for the global market. Furthermore, the increase in usage of monoclonal antibodies in various researches, cancer therapies is the key factor leading to growth of the market.Monoclonal Antibody Diagnostic Reagents Market was valued at US$ 8.5 billion in 2024 and is projected to grow at a CAGR of 12.3% to reach US$ 27.2 billion by 2034.

Region Analysis:

In the monoclonal antibody diagnostic reagents market, North America is expected to account major market share as compared to that of other regions in terms of revenue, owing to well-designed laboratories, increase in investments, supports from government. Asia-Pacific is expected to show high inclination growth rate due to changing lifestyle, inducing diseases coupled, as well as rising demand of diagnosis.

Key Development:

• In December 2020, the United States Food and Drug Administration approved MacroGenics' MARGENZATM for the treatment of patients with pre-treated metastatic HER2-positive breast cancer.
• In August 2020, the United States Food and Drug Administration provided approval to GlaxoSmithKline's belantamab mafodotin-blmf (BLENREP) for the treatment of relapsed or refractory multiple myeloma

Segmentation:

Monoclonal Antibody Diagnostic Reagents Market was valued at US$ 8.5 billion in 2024 and is projected to grow at a CAGR of 12.3% to reach US$ 27.2 billion by 2034. The Global Monoclonal Antibody Diagnostic Reagents Market is segmented by Diagnostic tests, Application and Region.

• By diagnostic tests, the Global Monoclonal Antibody Diagnostic Reagents Market is segmented into Double Antigen Sandwich Chemiluminescence Method, Dot-immunogold Filtration Assay, Recombinant Immunoblot Assay, and Enzyme Linked Immunosorbent Assay.
• By application, the Global Monoclonal Antibody Diagnostic Reagents Market is classified into Tumor Monitoring, Hormones Diagnosis, Virus Detection, and others.
• By region North America is expected to account major market share in Global Monoclonal Antibody Diagnostic Reagents Market, followed by other regions.

Competitive Analysis:                                                                                                 

The key players operating in the global monoclonal antibody diagnostic reagents market includes AnaSpec, Bio-Rad, BioGenex, BioVision, BioCare Medical, Creative Diagnostics, GenWay Biotech, Celltrion, MedixBiochemica, Innovent Biologics, Qiagen, and Teva Pharmaceutical Ltd.